Table 3—

Patient-reported medication use during the past 14 days by asthma severity grade

IntermittentMild persistentModerate persistentSevere persistent
Subjects n17413415339
No asthma drug therapy %12.1*0.8*0.0*0.0*
Specific asthma drug therapy %
 SABA alone21.8*17.2*11.1*10.3*
 LABA alone4.03.71.32.6
 SABA+LABA#0.04.52.02.6
 SABA+ICS1.7*11.2*13.7*5.1*
 LABA+ICS10.3*17.2*18.3*7.7*
 SABA+LABA+ICS2.3*11.2*15.0*12.8*
 ICS35.1*66.4*75.2*64.1*
  Low-dose+ ICS54.136.021.716.0
  Medium-dose+ ICS36.142.731.316.0
  High-dose+ ICS9.821.347.068.0
 LTRA10.913.412.415.4
 Oral corticosteroids4.0*5.2*15.7*33.3*
 Nasal corticosteroids29.934.328.818.0
 Antihistamines27.021.619.615.4
 Antibiotics6.33.74.60.0
 Allergen immunotherapy15.610.46.52.5
 Alternative medicine2.33.71.35.1
  • SABA: short-acting β2-agonist (inhaled)

  • LABA: long-acting β2-agonist (inhaled)

  • ICS: inhaled corticosteroids

  • LTRA: leukotriene receptor antagonist

  • #: without other drugs

  • : in any dose or combination

  • +: Global Initiative for Asthma recommended ICS dose levels 12

  • *: p<0.05 overall association between severity and the medication use (Chi-squared test for homogeneity)